Journal
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
Volume 10, Issue 3, Pages 349-354Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152711794653878
Keywords
Amyloid; peptidase; neurodegeneration; neurotransmission; Parkinson's disease; prolyl oligopeptidase; synuclein
Categories
Funding
- EU [FP7-HEALTH-2007-B, 223077]
- Flanders Research Foundation (FWO) [G.0114.08]
Ask authors/readers for more resources
Prolyl oligopeptidase ( PO) interacts with alpha-synuclein in vitro. It is a weak interaction that induces a nucleation prone conformation of alpha-synuclein. PO accelerates aggregation and fibril formation of alpha-synuclein in a process that can be reversed by specific inhibitors and is also influenced by an impairing mutation in the PO active site. There is evidence that PO and alpha-synuclein also interact intracellularly, especially in conditions where the expression of alpha-synuclein is high. Specific PO inhibitors reduce the number of cells with alpha-synuclein inclusions in a cellular model of Parkinson's disease. If these interactions also exist in the human brain, PO may be a target for the treatment of Parkinson's disease and other synucleinopathies. Whether PO also contributes to the normal physiological functions of alpha-synuclein remains an open question, but there are some intriguing parallels between the proposed functions of both proteins that deserve further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available